← Back to Search

Antiretroviral

Trizivir for HIV

Phase 3

Waitlist Available

Research Sponsored by Glaxo Wellcome

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patients must be currently receiving one of the following anti-HIV drug combinations: Combivir plus abacavir, Combivir plus abacavir plus a protease inhibitor, or Combivir plus abacavir plus a non-nucleoside reverse transcriptase inhibitor (NNRTI). Patients must have been taking this drug combination for at least the past 16 weeks, and this must be the first anti-HIV drug combination the patient has received

Patients must be at least 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial will compare the safety and effectiveness of Trizivir, a pill combining three anti-HIV drugs, to a combination of two drugs currently used to treat HIV.

Who is the study for?

This trial is for adults over 18 who are HIV-positive and have been on a specific anti-HIV drug combo including Combivir and abacavir for at least 16 weeks. They must be first-time recipients of this treatment, with low viral loads (≤400 copies/ml) and sufficient immune cell counts (CD4+ >200 cells/mm3). Participants need to commit to birth control use but can't join if they have hepatitis, severe conditions like heart disease or diabetes, allergies to study drugs, substance abuse issues, or if they're pregnant/breastfeeding.Check my eligibility

What is being tested?

The trial tests the safety and effectiveness of Trizivir—a single pill combining three anti-HIV medications: zidovudine, lamivudine, and abacavir—against the standard regimen of Combivir plus abacavir. The goal is to see if combining these drugs into one pill offers similar benefits.See study design

What are the potential side effects?

Potential side effects include allergic reactions especially to abacavir which could be life-threatening in rare cases. Other common side effects may involve nausea, headaches, fatigue, digestive problems; long-term risks include blood disorders like anemia or bone marrow suppression.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am on my first HIV treatment regimen, which includes Combivir and abacavir, for at least 16 weeks.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Glaxo WellcomeLead Sponsor

120 Previous Clinical Trials

24,200 Total Patients Enrolled

Media Library

Abacavir (Antiretroviral) Clinical Trial Eligibility Overview. Trial Name: NCT00004981 — Phase 3

Human Immunodeficiency Virus Infection Research Study Groups:

Human Immunodeficiency Virus Infection Clinical Trial 2023: Abacavir Highlights & Side Effects. Trial Name: NCT00004981 — Phase 3

Abacavir (Antiretroviral) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00004981 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this treatment effective and safe for human patients?

"This is a Phase 3 trial, which means that while there is data supporting the efficacy of the treatment, there have been multiple rounds of data collection supporting its safety. Therefore, our team rates the safety of the treatment as a 3."

Answered by AI

Does this research project span multiple sites?

"Currently, this trial is recruiting patients from 25 different locations, which include cities such as Galveston, Washington, Tampa, and others. To reduce the amount of travel required, please enroll at the location nearest to you."

Answered by AI

Is this clinical trial only for adults, or are minors also allowed to participate?

"Based on the age requirements listed in the inclusion criteria for this study, the minimum age for participation is 18 and there is no maximum age limit."

Answered by AI

Who meets the necessary requirements to participate in this research?

"The requirements for this trial are that participants are HIV-positive and between the ages of 18 and 50. There are plans to have a total of 230 individuals enrolled in the study."

Answered by AI